Caldiran, F. Et Al. 2023. Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells. Biochemical and Biophysical Research Communications , vol.675 , 33-40.

Caldiran, F., Berkel, C., Yilmaz, E., Kucuk, B., Cacan, A. H., ÇİTLİ, Ş., ... Canpolat, E.(2023). Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells. Biochemical and Biophysical Research Communications , vol.675, 33-40.

Caldiran, Feyzanur Et Al. "Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells," Biochemical and Biophysical Research Communications , vol.675, 33-40, 2023

Caldiran, Feyzanur Et Al. "Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells." Biochemical and Biophysical Research Communications , vol.675, pp.33-40, 2023

Caldiran, F. Et Al. (2023) . "Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells." Biochemical and Biophysical Research Communications , vol.675, pp.33-40.

@article{article, author={Feyzanur Caldiran Et Al. }, title={Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells}, journal={Biochemical and Biophysical Research Communications}, year=2023, pages={33-40} }